Reading and Resources

Resources

American Diabetes Association (ADA). Summary of the ADA type 1 diabetes screening & awareness roundtable.
From December 15, 2023.
https://diabetes.org/sites/default/files/2024-04/ADA-T1D-Screening-and-Awareness-Roundtable-Report.pdf

TrialNet: Resources for Healthcare Providers
https://www.trialnet.org/healthcare-providers

Breakthrough T1D (formerly JDRF). Information on T1D Clinical Trials
https://www.breakthrought1d.org/clinical-trials/

University of Colorado – Barbara Davis Center for Diabetes. Ask the experts for early T1D answers and guidance
https://www.asktheexperts.org/

Breakthrough T1D (formerly JDRF). Information on early T1D detection.
https://www.breakthrought1d.org/early-detection/

TrialNet. Resources for T1D Screening & national T1D Screening Program.
https://www.trialnet.org/

ASK (Autoimmunity Screening for Kids). T1D Screening Program.
https://www.askhealth.org/

PLEDGE (Population Level Estimate of type 1 Diabetes risk Genes in Children). T1D Screening Program at Sanford Health in South Dakota.
https://research.sanfordhealth.org/fields-of-research/diabetes/pledge

CASCADE Research Study. T1D Screening Program at Pacific Northwest Research Institute in Washington.
https://cascadekids.org/

stopT1D
https://mlgcme.com/stopt1d

Suggested reading materials

American Diabetes Association. 2. Diagnosis and classification of diabetes: standards of care in diabetes – 2024. Diabetes Care. 2024;47(suppl 1):S20-S42. https://diabetesjournals.org/care/article/47/Supplement_1/S20/153954
American Diabetes Association. 3. Prevention or delay of diabetes and associated comorbidities: standards of care in diabetes – 2024. Diabetes Care. 2024;47(suppl 1):S43-S51. https://diabetesjournals.org/care/article/47/Supplement_1/S43/153945
Besser RE, Bell KJ, Couper JJ, et al. ISPAD clinical practice consensus guidelines 2022: stages of type 1 diabetes in children and adolescents. Pediatric diabetes. 2022;23:1175-1187. https://cdn.ymaws.com/www.ispad.org/resource/resmgr/consensus_guidelines_2018_/guidelines2022/ch._2_pediatric_diabetes_-_2.pdf
Herold KC, Bundy BN, Long SA, et al. An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes. N Engl J Med. 2019;381:603-613. https://www.nejm.org/doi/full/10.1056/NEJMoa1902226
Herold KC, Gitelman SE, Gottlieb PA, et al. Teplizumab: a disease-modifying therapy for type 1 diabetes that preserves β-cell function. Diabetes Care. 2023;46:1848-1856. https://diabetesjournals.org/care/article/46/10/1848/153536/Teplizumab-A-Disease-Modifying-Therapy-for-Type-1
Insel RA, Dunne JL, Atkinson MA, et al. Staging presymptomatic type 1 diabetes: A scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes care. 2015;38:1964-1974. https://diabetesjournals.org/care/article/38/10/1964/37704/Staging-Presymptomatic-Type-1-Diabetes-A
Leslie RD, Evans-Molina C, Freund-Brown J, et al. Adult-onset type 1 diabetes: Current understanding and challenges. Diabetes Care. 2021;44:2449-2456. https://diabetesjournals.org/care/article/44/11/2449/138477/Adult-Onset-Type-1-Diabetes-Current-Understanding
Mehta S, Ryabets-Lienhard A, Patel N, et al. Pediatric Endocrine Society statement on considerations for use of teplizumab (Tzield^™) in clinical practice. Horm Res Paediatr. 2024;1663-2826. https://karger.com/hrp/article/doi/10.1159/000538775/906682/Pediatric-Endocrine-Society-Statement-on
Ramos EL, Dayan CM, Chatenoud L, et al. Teplizumab and β-cell function in newly diagnosed type 1 diabetes. N Engl J Med. 2023;389:2151-2161. https://www.nejm.org/doi/full/10.1056/NEJMoa2308743
Simmons KM, Sims EK. Screening and prevention of type 1 diabetes: Where are we? J Clin Endocrinol Metab. 2023;108:3067-3079. https://academic.oup.com/jcem/article-abstract/108/12/3067/7192350
Sims EK, Besser REJ, Dayan C, et al. Screening for type 1 diabetes in the general population: A status report and perspective. Diabetes. 2022;71:610-623. https://diabetesjournals.org/diabetes/article/71/4/610/144874/Screening-for-Type-1-Diabetes-in-the-General

Reading and Resources

Resources

Suggested reading materials

Etiopathogenesis of T1D

Clinical Presentation and Natural History of T1D

Early Screening and Detection

Advances in Delaying T1D Progression

Patient Support Strategies and Practice Implications

Reading and Resources

For optimized Clinical Trial Tracker use, please utilize Chrome or Firefox browsers

Reading and Resources

Resources

Suggested reading materials

Etiopathogenesis of T1D

Clinical Presentation and Natural History of T1D

Early Screening and Detection

Advances in Delaying T1D Progression

Patient Support Strategies and Practice Implications

Reading and Resources

Pin It on Pinterest

For optimized Clinical Trial Tracker use, please utilize Chrome or Firefox browsers